EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer

Mitchell Machtay iD, Pedro A Torres-Saavedra iD, Wade Thorstad iD, Phuc Felix Nguyen-Tân, Lillian L Siu, F Christopher Holsinger iD, Adel El-Naggar, Christine Chung iD, Anthony Cmelak iD, Barbara Burtness iD, Greg Bednarz, Harry Quon iD und 18 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-01829 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Mitchell Machtay und 29 weiteren Autor:innen. Beteiligte Einrichtung: Penn State Milton S Hershey Medical Center, Hershey, PA. Hauptthemen laut MEDLINE: Cetuximab, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Radiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk cancer. METHODS Patients had squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity, oropharynx, or larynx, with one or more risk factors warranting postoperative RT. Patients were randomly assigned 1:1 to intensity-modulated RT (60-66 Gy) with once-per-week C or RT alone. The primary hypothesis was that RT + C would improve overall survival (OS) in randomly assigned/eligible patients, with a prespecified secondary plan to test this in the human papillomavirus (HPV)–negative subpopulation. Disease-free survival (DFS) and toxicity were secondary end points. OS and DFS were tested via stratified log-rank test; toxicity was compared via Fisher's exact test. RESULTS We enrolled 702 patients from November 2009 to March 2018; 577 were randomly assigned/eligible. Most (63.6%) had oral cavity cancer and most (84.6%) had high epidermal growth factor receptor expression. There were fewer deaths (184) than expected. OS (median follow up, 7.2 years) was not significantly improved (hazard ratio [HR], 0.81; one-sided P = .0747; 5-year OS 76.5% v 68.7%), but DFS was (HR, 0.75; one-sided P = .0168; 5-year DFS 71.7% v 63.6%). Benefit of RT + C was only seen in the HPV-negative subpopulation (80.2% of patients in the trial). Grade 3-4 acute toxicity rates were 70.3% (RT + C) versus 39.7% (RT; two-sided P < .0001), mostly skin and/or mucosal effects. Late grade ≥3 toxicity rate was 33.2% (RT + C) versus 29.0% (RT; two-sided P = .3101). There were no grade 5 toxicities in either arm. CONCLUSION RT + C significantly improved DFS, but not OS, with no increase in long-term toxicity, compared with RT alone for resected, intermediate-risk SCCHN. RT + C is an appropriate option for carefully selected patients with HPV-negative disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CetuximabHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAntineoplastic Agents, ImmunologicalRadiotherapy, Intensity-ModulatedHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overRadiotherapy, AdjuvantDisease-Free Survival

Substanzen

CetuximabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Penn State Milton S Hershey Medical Center, Hershey, PA.
  • Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
  • NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
  • Washington University School of Medicine, Saint Louis, MO.
  • CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada.
  • University Health Network-Princess Margaret Hospital, Toronto, ON, Canada.

ORCID-Profile: Mitchell Machtay, Pedro A Torres-Saavedra, Wade Thorstad, F Christopher Holsinger, Christine Chung, Anthony Cmelak, Barbara Burtness, Harry Quon, Clement K Gwede, Adam P Dicker, Jennifer Dorth, Nancy Lee, Jason W Chan, William A Stokes, Arnab Chakravarti, David Sher, Sue S Yom, Quynh-Thu Le

Förderung

  • NCI NIH HHS

Zitieren

APA

Machtay, M., Torres-Saavedra, P. A., Thorstad, W., Nguyen-Tân, P. F., Siu, L. L., Holsinger, F. C., El-Naggar, A., Chung, C., Cmelak, A., Burtness, B., Bednarz, G., Quon, H., Breen, S. L., Gwede, C. K., Dicker, A. P., Yao, M., Jordan, R. C., Dorth, J., Lee, N., …, & NRG Oncology RTOG 0920 Collaborating Team (2025). Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01829

Vancouver

Machtay M, Torres-Saavedra PA, Thorstad W, Nguyen-Tân PF, Siu LL, Holsinger FC, et al. Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01829

BibTeX
@article{Machtay2025,
  author = {Machtay, Mitchell and Torres-Saavedra, Pedro A and Thorstad, Wade and Nguyen-Tân, Phuc Felix and Siu, Lillian L and Holsinger, F Christopher and El-Naggar, Adel and Chung, Christine and Cmelak, Anthony and Burtness, Barbara and Bednarz, Greg and Quon, Harry and Breen, Stephen L and Gwede, Clement K and Dicker, Adam P and Yao, Min and Jordan, Richard C and Dorth, Jennifer and Lee, Nancy and Chan, Jason W and Dunlap, Neal and Bar-Ad, Voichita and Stokes, William A and Chakravarti, Arnab and Sher, David and Rao, Shyam and Harris, Jonathan and Yom, Sue S and Le, Quynh-Thu and NRG Oncology RTOG 0920 Collaborating Team, NRG Oncology RTOG 0920 Collaborating Team},
  title = {Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-01829}
}
Kostenlos starten →